Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANGN NYSEAMERICAN:PFNX NASDAQ:SNSE NASDAQ:TERN NASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGNAngion Biomedica$6.48$0.46▼$2.04$30.11M0.686,718 shs224,800 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASNSESensei Biotherapeutics$9.02+0.2%$8.07$5.00▼$17.40$11.37M0.2760,004 shs1,556 shsTERNTerns Pharmaceuticals$8.18+10.5%$6.42$1.87▼$10.70$715.83M-0.041.16 million shs843,192 shsTHTarget Hospitality$8.59-0.1%$8.26$4.00▼$11.10$857.11M2585,029 shs538,145 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGNAngion Biomedica0.00%0.00%0.00%0.00%0.00%PFNXPfenex0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics+1.98%+4.29%+8.83%+20.32%-12.62%TERNTerns Pharmaceuticals+1.37%-0.94%+9.47%+85.00%-23.16%THTarget Hospitality-0.81%-2.05%+6.83%+21.47%-12.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGNAngion Biomedica$6.48$0.46▼$2.04$30.11M0.686,718 shs224,800 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASNSESensei Biotherapeutics$9.02+0.2%$8.07$5.00▼$17.40$11.37M0.2760,004 shs1,556 shsTERNTerns Pharmaceuticals$8.18+10.5%$6.42$1.87▼$10.70$715.83M-0.041.16 million shs843,192 shsTHTarget Hospitality$8.59-0.1%$8.26$4.00▼$11.10$857.11M2585,029 shs538,145 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGNAngion Biomedica0.00%0.00%0.00%0.00%0.00%PFNXPfenex0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics+1.98%+4.29%+8.83%+20.32%-12.62%TERNTerns Pharmaceuticals+1.37%-0.94%+9.47%+85.00%-23.16%THTarget Hospitality-0.81%-2.05%+6.83%+21.47%-12.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGNAngion Biomedica 0.00N/AN/AN/APFNXPfenex 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$55.00509.62% UpsideTERNTerns Pharmaceuticals 2.67Moderate Buy$15.4989.34% UpsideTHTarget Hospitality 3.00Buy$13.0051.34% UpsideCurrent Analyst Ratings BreakdownLatest ANGN, TH, PFNX, TERN, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025TERNTerns PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.009/16/2025TERNTerns PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.009/4/2025TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.448/19/2025THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$7.50 ➝ $11.008/5/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGNAngion Biomedica$2.30M0.00N/AN/A$1.32 per share0.00PFNXPfenexN/AN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ATHTarget Hospitality$386.27M2.22$1.47 per share5.84$4.26 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGNAngion Biomedica-$38.81MN/A0.00N/AN/AN/A-47.53%-40.55%N/APFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$30.16M-$21.31N/AN/AN/AN/A-72.13%-61.35%11/13/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)THTarget Hospitality$71.26M$0.1085.9023.86N/A3.58%3.26%2.13%11/11/2025 (Estimated)Latest ANGN, TH, PFNX, TERN, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025THTarget Hospitality-$0.11-$0.15-$0.04-$0.15$56.43 million$61.61 million8/5/2025Q2 2025SNSESensei Biotherapeutics-$6.20-$3.91+$2.29-$3.91N/AN/A8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGNAngion BiomedicaN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGNAngion BiomedicaN/A20.0020.00PFNXPfenexN/AN/AN/ASNSESensei BiotherapeuticsN/A7.647.64TERNTerns PharmaceuticalsN/A24.7024.70THTarget Hospitality0.071.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGNAngion Biomedica17.00%PFNXPfenexN/ASNSESensei Biotherapeutics10.50%TERNTerns Pharmaceuticals98.26%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipANGNAngion Biomedica19.70%PFNXPfenexN/ASNSESensei Biotherapeutics23.20%TERNTerns Pharmaceuticals1.50%THTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANGNAngion Biomedica330.11 million24.18 millionNot OptionablePFNXPfenex7134.30 millionN/ANot OptionableSNSESensei Biotherapeutics401.26 million968,000Not OptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableTHTarget Hospitality82099.78 million31.93 millionNot OptionableANGN, TH, PFNX, TERN, and SNSE HeadlinesRecent News About These CompaniesInspire Investing LLC Invests $344,000 in Target Hospitality Corp. $THSeptember 17 at 3:25 AM | marketbeat.comTarget Hospitality Releases New Investor PresentationSeptember 16 at 7:21 PM | msn.comTarget Hospitality (NASDAQ:TH) Cut to "Sell" at Wall Street ZenSeptember 15 at 2:07 AM | marketbeat.comTarget Hospitality Corp. (NASDAQ:TH) Short Interest UpdateSeptember 10, 2025 | marketbeat.comPhiladelphia Financial Management of San Francisco LLC Invests $11.44 Million in Target Hospitality Corp. $THSeptember 8, 2025 | marketbeat.comPDT Partners LLC Purchases New Shares in Target Hospitality Corp. $THSeptember 6, 2025 | marketbeat.comNuveen LLC Acquires Shares of 87,749 Target Hospitality Corp. $THSeptember 6, 2025 | marketbeat.comAppian Way Asset Management LP Invests $11.87 Million in Target Hospitality Corp. $THSeptember 4, 2025 | marketbeat.comQ2 Earnings Roundup: Target Hospitality (NASDAQ:TH) And The Rest Of The Travel and Vacation Providers SegmentSeptember 1, 2025 | finance.yahoo.comTarget Hospitality Corp. $TH Shares Purchased by American Century Companies Inc.August 31, 2025 | marketbeat.com241,551 Shares in Target Hospitality Corp. $TH Bought by Kore Advisors LPAugust 30, 2025 | marketbeat.com50,394 Shares in Target Hospitality Corp. $TH Acquired by Aristides Capital LLCAugust 28, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded by Wall Street Zen to "Hold" RatingAugust 25, 2025 | marketbeat.comTarget Hospitality (TH) Stock Is Up, What You Need To KnowAugust 22, 2025 | msn.comTarget Hospitality (NASDAQ:TH) Stock Price Up 3.1% Following Analyst UpgradeAugust 22, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Shares Gap Up on Analyst UpgradeAugust 21, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded to "Buy" at Stifel NicolausAugust 21, 2025 | marketbeat.comStifel Upgrades Target Hospitality (TH)August 20, 2025 | msn.comTarget Hospitality Corp. $TH Shares Bought by Connor Clark & Lunn Investment Management Ltd.August 20, 2025 | marketbeat.comWhy Are Target Hospitality (TH) Shares Soaring TodayAugust 19, 2025 | msn.comTarget Hospitality's diversification strategy and data center contract earns new bullAugust 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025The Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025ANGN, TH, PFNX, TERN, and SNSE Company DescriptionsAngion Biomedica NASDAQ:ANGNAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Sensei Biotherapeutics NASDAQ:SNSE$9.02 +0.02 (+0.24%) Closing price 03:58 PM EasternExtended Trading$8.80 -0.22 (-2.47%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Terns Pharmaceuticals NASDAQ:TERN$8.18 +0.78 (+10.54%) Closing price 04:00 PM EasternExtended Trading$8.17 -0.01 (-0.12%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Target Hospitality NASDAQ:TH$8.59 -0.01 (-0.12%) Closing price 04:00 PM EasternExtended Trading$8.59 0.00 (0.00%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
